Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?

doi:10.1186/1741-7015-10-20

Back to search

Article

Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?

BMC medicine - 23 Feb 2012

Rudenko Iakov N, Chia Ruth, Cookson Mark R

Abstract excerpt

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are a common cause of familial Parkinson's disease (PD). Variation around the LRRK2 locus also contributes to the risk of sporadic PD. The LRRK2 protein contains a central catalytic region, and pathogenic mutations cluster in the Ras of c...

Topics

Animals
Clinical Trials as Topic
Humans
Mutation
Parkinson Disease
Protein Kinase Inhibitors
Protein Serine-Threonine Kinases
Translational Research, Biomedical

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.